display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HR positive
la/mBC - HR-positive - 2nd line (L2)
HDAC inhibitor
entinostat plus exemestane ENCORE301 E2112
tucidinostat based treatment
tucidinostat plus exemestane ACE

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons